论文部分内容阅读
★美国FDA批准抗高血压复方制剂Exforge上市该制剂以单片剂型结合了2种常用的高血压药物:血管紧张素受体拮抗剂(ARB)类药物缬沙坦和钙离子通道拮抗剂(CCB)类药物氨氯地平。一项入选5000多例患者的大型临床试验为此次做出的最终批准提供了支持数据。在两项安慰剂对照试验中,接受
★ FDA Approves Anti-Hypertension Compound Formulation Exforge to Market The formulation combines two commonly used antihypertensive drugs in a single dosage form: the angiotensin receptor blocker (ARB) drug valsartan and the calcium channel blocker (CCB A class of drugs amlodipine. A large clinical trial of more than 5000 patients was selected to provide support data for this final approval. In two placebo-controlled trials, accept